EP1037610A1 - Compositions a base de liposomes renfermant de la camptothecine - Google Patents

Compositions a base de liposomes renfermant de la camptothecine

Info

Publication number
EP1037610A1
EP1037610A1 EP98946983A EP98946983A EP1037610A1 EP 1037610 A1 EP1037610 A1 EP 1037610A1 EP 98946983 A EP98946983 A EP 98946983A EP 98946983 A EP98946983 A EP 98946983A EP 1037610 A1 EP1037610 A1 EP 1037610A1
Authority
EP
European Patent Office
Prior art keywords
liposome
gil
phosphatidylcholine
ammonium
camptothecin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98946983A
Other languages
German (de)
English (en)
Other versions
EP1037610A4 (fr
Inventor
Karen Lewis Moynihan
David Lloyd Emerson
Su-Ming Chiang
Ning Hu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OSI Pharmaceuticals LLC
Original Assignee
Nexstar Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexstar Pharmaceuticals Inc filed Critical Nexstar Pharmaceuticals Inc
Publication of EP1037610A1 publication Critical patent/EP1037610A1/fr
Publication of EP1037610A4 publication Critical patent/EP1037610A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • This invention relates to the fields of biochemistry and medicine, and in particular to novel liposomal formulations and process for making such formulations. More specifically, this invention relates to liposomal formulations containing camptothecin and analogs thereof. Further, this invention relates to methods of manufacturing and of using such formulations.
  • Camptothecin is a pentacyclic plant alkaloid originally isolated from the bark of Camptotheca accuminata trees indigenous to China (Wall et al., J. Am. Chem. Soc, 94: 388 (1966)).
  • the drug contains a fused ring structure incorporating quinoline, pyrrolidine, alpha-pyridone and a six membered lactone ring.
  • the naturally occurring form of camptothecin is optically active, with the asymmetric carbon atom at position 20 of the lactone ring in the "S" configuration.
  • camptothecins Camptothecin and numerous analogs thereof (hereafter termed camptothecins) are currently the focus of intensive study due to the potent anti-tumor activity displayed by these compounds both in vitro and in vivo (e.g., Giovanella, et al, Science 246: 1046-1048 (1989)).
  • the cytotoxic effects of camptothecins have also been exploited in their use as anti-viral, anti-Plasmodium and anti-haemoflagellate agents (Priel et al, U.S. Patent No. 5,622,959; Priel et al, U.S. Patent No. 5,422,344; Atlas, WO 9611005; Wall et al, U.S. Patent No. 5,614,529; Shapiro et al, U.S. Patent No. 5,496,830; Pardee, WO 9404160).
  • Camptothecin drugs are believed to exert their anti-tumor effect by binding to and reversibly inhibiting the action of the enzyme topoisomerase I.
  • This enzyme is required for DNA and RNA synthesis in proliferating cells, where it catalyses the relaxation of supercoiled DNA structures that form during these processes.
  • camptothecins include a number of drawbacks.
  • the lactone ring is susceptible to hydrolysis at the pH of blood plasma, resulting in a carboxylate form of the drug that has significantly reduced topoisomerase activity (Fassberg and Stella (1992) J. Pharm. Sci. 81(7):676-689; Mi et al. (1995) Biochemistry 34(42):13722-13728; Potmesil (1994) Cancer Res. 54:1431-1439; Slichenmyer et al. (1993) J. Natl. Cancer Inst.
  • camptothecin derivatives with increased water solubility, decreased toxicity and increased resistance to hydrolysis.
  • Two examples are topotecan (Hycamtin TM ) (Kingsbury et al, J. Med. Chem. 34:98 (1991); Boehm et al., European Patent Application No. 321,122) which is approved for salvage therapy of metastatic ovarian carcinoma, and irinotecan (Miysaka et al., U.S. Patent No. 4,604,463) which is approved for salvage therapy of colon cancer.
  • Other derivatives of camptothecin and anti-tumor treatments using these derivatives are described in Wall et al. (U.S. Patent No. 5,340,817); Wall et al. (U.S. Patent No. 5,364,858); Wall et al. (U.S. Patent No. 5,244,903); Wall (U.S. Patent
  • Insoluble, hydrolyzable compounds may be administered in a clinical situation by packaging the compounds into lipid aggregates or constructs such as liposomes or micelles.
  • Liposomes are known to be physiologically compatible and biodegradable delivery systems for a broad range of drugs.
  • an insoluble compound can be delivered to the site of action in a more concentrated and easily administered medicament than the free drug alone.
  • Burke U.S. Patent No. 5,552,156 discloses liposome-associated camptothecins in which it is postulated that the lactone ring of the camptothecin intercalates with the acyl chains of the lipid bilayer. The lactone ring is effectively removed from the aqueous
  • concentration-time curve was obtained from liposomal versus free camptothecin, although the increase of the AUC was only about 4 fold higher.
  • Camptothecins incorporated within vesicles and liposomes are also described in
  • the present invention provides for liposomal formulations of camptothecin and its structurally related analogs as well as methods for their preparation.
  • the liposomes have improved pharmacokinetics, enhanced efficacy as anti-tumor agents, and provide an improved therapeutic index as compared to the free drug.
  • the formulations include liposomes comprising at least one phospholipid and a camptothecin or analog thereof (referred to collectively herein as "camptothecin").
  • the formulations include liposomes comprised of cholesterol, a phosphatidylcholine, an excipient, wherein the
  • excipient is sulfate or citrate, and a camptothecin, wherein a portion of the camptothecin may
  • camptothecin for use in this invention is Gil 47211. Further, the formulations
  • Figure 1 depicts the precipitation of Gil 4721 1 with various counterion excipients.
  • Figure 2 depicts the stability in two representative liposomal Gil 47211 lots prepared
  • Figures 3A-3D show liposomal Gil 47211 cytotoxicity vs. Gil 47211 and topotecan (TP).
  • SKOV-3 ovarian carcinoma
  • Figure 4A-4D show liposomal Gil 47211 cytotoxicity v. Gil 47211 and empty liposome
  • IC 50 values (ng/ml) calculated for each data set are presented below each panel graph. All tumor cell types are of human derivation.
  • ⁇ GI14721 IC
  • ⁇ liposomal GI14721 1 (Lot # ALM 993-028)
  • T T
  • Figure 5 is a pharmacokinetic comparison of DSPC and HSPC containing liposomal
  • Figure 6 is a pharmacokinetic comparison of free drug and liposomal GI147211
  • Figure 8 shows the lipid hydrolysis rate for liposomal Gil 47211 (citric acid) with and without the addition of ammonium chloride to the final buffer.
  • Formulations comprising camptothecin encapsulated in a liposome are provided as well as methods of their preparation.
  • the formulations have pharmaceutical uses, including as anti -tumor or anti-viral agents.
  • the liposomes have improved pharmacokinetics, enhanced efficacy as anti-tumor agents, and provide an improved therapeutic index as compared to the free drug.
  • the formulations include liposomes comprised of at least one phospholipid and a camptothecin. Additionally, it is also contemplated by this invention to optionally include a sterol, such as cholesterol and/or a cholesterol analog, in the liposomal formulation.
  • the formulations include liposomes comprised of cholesterol, a phosphatidylcholine, an excipient, wherein the excipient is sulfate or citrate, and a camptothecin.
  • a portion of the camptothecin may be precipitated in the aqueous interior of the liposomes by the excipient.
  • the formulations described herein are stable upon storage.
  • the liposomes are unilamellar vesicles having a size less than 200 nm, most preferably less than
  • phospholipid is distearoylphosphatidylcholine (DSPC) and includes
  • the liposomes are unilamellar vesicles having a size less than 200 nm, most preferably less than 100 nm, wherein the phospholipid is hydrogenated soy phosphatidylcholine (HSPC) and includes cholesterol in a 2:1 molar ratio and the camptothecin is GI 147211.
  • the lipid amptothecin molar ratios are 5:1 to 100:1, more preferrably 10:1 to 40:1, and most preferably 15:1 to 25:1.
  • Liposome refers to unilamellar vesicles or multilamellar
  • Unilamellar liposomes also referred to as “single lamellar vesicles,” are spherical vesicles comprised of one lipid bilayer membrane which defines a single closed aqueous compartment.
  • the bilayer membrane is composed of two layers of lipids; an inner layer and an outer layer (leaflet).
  • the outer layer of the lipid molecules are oriented with their hydrophilic head portions toward the external aqueous environment and their hydrophobic tails pointed downward toward the interior of the liposome.
  • the inner layer of the lipid lays directly beneath the outer layer, the lipids are oriented with their heads facing the aqueous interior of the liposome and their tails toward the tails of the outer layer of lipid.
  • Multilamellar liposomes also referred to as “multilamellar vesicles” or “multiple lamellar vesicles,” are composed of more than one lipid bilayer membrane, which membranes define more than one closed aqueous compartment.
  • the membranes are
  • encapsulation and "entrapped.” as used herein, refer to the incorporation or association of the camptothecin in or with a liposome.
  • the camptothecin may be associated with the lipid bilayer or present in the aqueous interior of the liposome, or both.
  • a portion of the encapsulated camptothecin takes the form of a precipitated salt in the interior of the liposome.
  • the drug may also self precipitate in the interior of the liposome.
  • excipient refers to a substance that can initiate or facilitate drug loading and may also initiate or facilitate precipitation of the camptothecin in the aqueous interior of the liposome.
  • excipients include, but are not limited to, the acid, sodium or ammonium forms of
  • monovalent anions such as chloride, acetate, lactobionate and formate
  • divalent anions such as aspartate, succinate and sulfate
  • trivalent ions such as citrate and phosphate.
  • Preferred excipients are citrate and sulfate.
  • camptothecin refers to camptothecin and any and all related analogs or derivatives thereof which exhibit anti-tumor activity. Camptothecin drugs generally have the same core ring system. Various modifications or substitutions are found in many camptothecins, preferably such modifications or substitutions are seen in rings A and B. The camptothecin drugs generally have a similar structure that can exist as lactone and carboxylate forms as shown below. As used herein, camptothecin refers to both the lactone and carboxylate forms.
  • camptothecin drugs are provided in Table 1.
  • camptothecin drugs have the following structure:
  • n may be 1-4.
  • R, is Cl
  • the drug is 9-chloro-10,l 1- methylenedioxycamptothecin
  • when R, is NH 2 the drug is 9-amino-10,l 1- methylenedioxycamptothecin
  • R, is H the drug is 10,11- methylenedioxycamptothecin.
  • GI14721 IC refers to the dihydrochloride salt
  • suffix "X" in GI 14721 IX refers to the free base
  • camptothecins may have either "A” and/or "B" ring substitutions.
  • the preferred camptothecins may have either "A” and/or "B” ring substitutions.
  • camptothecins include 7-(4-methylpiperazinomethylene)- 10,11 -ethylenedioxy-20(S)- camptothecin (Gil 47211), topotecan, and irinotecan (see Table 1), with the most preferred
  • camptothecin drug being Gil 47211.
  • Other camptothecins include, but are not limited to, 9- hydroxycamptothecin, 10-aminocamptothecin, 9-hydroxy-l O-dimethylaminomethyl camptothecin, 20-(RS)-10,l 1 methylendioxycamptothecin, 9-chloro-10,l 1 -methylenedioxy- (20S)-camptothecin, 7-ethyl-10-hydroxycamptothecin, and 7-ethyl-10-[[[4-(l-piperidino)-l- piperidino]carbonyl]-oxy]camptothecin.
  • Phospholipid refers to any one phospholipid or combination of phospholipids capable of forming liposomes.
  • Phosphatidylcholines including those obtained from egg, soy beans or other plant sources or those that are partially or wholly synthetic, or of variable lipid chain length and unsaturation are suitable for use in the present invention.
  • Synthetic, semisynthetic and natural product phosphatidylcholines including, but not limited to, distearoylphosphatidylcholine (DSPC), hydrogenated soy phosphatidylcholine (HSPC), soy phosphatidylcholine (soy PC), egg phosphatidylcholine (egg PC), hydrogenated egg phosphatidylcholine (HEPC), dipalmitoylphosphatidylcholine (DPPC) and dimyristoylphosphatidylchohne (DMPC) are suitable phosphatidylcholines for use in this invention. All of these phospholipids are commercially available. Preferred PCs are
  • HSPC and DSPC the most preferred is HSPC.
  • phosphatidylglycerols (PG) and phosphatic acid (PA) are also suitable phospholipids for use in the present invention and include, but are not limited to, dimyristoylphosphatidylglycerol (DMPG), dilaurylphosphatidylglycerol (DLPG), dipalmitoylphosphatidylglycerol (DPPG), distearoylphosphatidylglycerol (DSPG)
  • DMPA dimyristoylphosphatidic acid
  • DSPA distearoylphosphatidic acid
  • DLPA dilaurylphosphatidic acid
  • DPPA dipalmitoylphosphatidic acid
  • Distearoylphosphatidylglycerol is the preferred negatively charged lipid when used in formulations.
  • Other suitable phospholipids include phosphatidylethanolamines,
  • PEG polyethylene glycol
  • parenteral refers to intravenous (IV), intramuscular (IM), subcutaneous (SubQ) or intraperitoneal (IP) administration.
  • improved therapeutic index refers to a higher therapeutic index relative to the free drug.
  • the therapeutic index is expressed as a ratio of the lethal dose for 50% of the animals relative to the effective dose.
  • cholesterol in the liposomal formulation.
  • Cholesterol is known to improve liposome stability and prevent loss of phospholipid to lipoproteins in vivo. Any lipid amptothecin ratio that is efficacious is contemplated by this invention.
  • Preferred lipid:camptothecin molar ratios are 5:1 to 100:1, more preferably 10:1 to 40:1.
  • lipidxamptothecin molar ratios are 15:1 to 25:1.
  • Preferred liposomal formulations include phospholipidxholesterol molar ratios over the range of 1.5:0.5 to 2:1.5.
  • Most preferred liposomal formulation is 2:1 PCxhol with or without 1 to 4 mole percent PG.
  • the most preferred liposomal size is less than 100 nm.
  • the preferred loading effciency of drug is a percent encapsulated camptothecin of about 70% or greater.
  • Encapsulation includes molecules present in the interior aqueous space of the liposome, molecules in the inner or outer leaflet of the membrane bilayer, molecules partially buried in the outer leaflet of the bilayer and partially external to the liposome, and molecules associated with the surface of the liposome, e.g., by electrostatic interactions.
  • the process of preparing the formulation embodied in the present invention is initiated with the preparation of a solution from which the liposomes are formed. This is done, for example, by weighing out a quantity of a phosphatidylcholine, optionally cholesterol and optionally a phosphatidylglycerol and dissolving them in an organic solvent, preferably chloroform and methanol in a 1 : 1 mixture (v/v) or alternatively neat chloroform.
  • the solution is evaporated to form a solid lipid phase such as a film or a powder, for example, with a rotary evaporator, spray dryer or other means.
  • the film or powder is then hydrated with an aqueous solution containing an excipient having a pH range from 2.0 to 7.4 to form a liposome dispersion.
  • the preferred aqueous solution for purposes of hydration is a buffered solution of the acid, sodium or ammonium forms of citrate or
  • the preferred buffers are > 5mM, more preferably 50 mM, citric acid (pH 2.0 - 5.0), ammonium citrate (pH 2.0 - 5.5), or ammonium sulfate (pH 2.0 to 5.5). It would be known by one of skill in the art that other anionic acid buffers could be used, such as phosphoric acid.
  • the lipid film or powder dispersed in buffer is heated to a temperature from about
  • Multilamellar liposomes are formed by agitation of the dispersion, preferably through the use of a thin-film evaporator apparatus such as is described in U.S. Patent No. 4,935,171 or through shaking or vortex mixing.
  • Unilamellar vesicles are formed by the application of a shearing force to an aqueous dispersion of the lipid solid phase, e.g., by sonication or the use of a microfluidizing apparatus such as a homogenizer or a French press. Shearing force can also be applied using either injection, freezing and thawing, dialyzing away a detergent
  • liposomes can be controlled using a variety of known techniques including the duration of shearing force.
  • a homogenizing apparatus is employed to form unilamellar vesicles having diameters of less than 200 nanometers at a pressure of 3,000 to 14,000 psi, preferably 10,000 to 14,000 psi and a temperature of about the aggregate transition temperature of the lipids.
  • Unentrapped excipient is removed from the liposome dispersion by buffer exchange to 9% sucrose using either dialysis, size exclusion column chromatography (Sephadex G-50 resin) or ultrafiltration (100,000 - 300,000 molecular weight cut off).
  • Each preparation of small unilamellar liposomes is then actively loaded with Gil 47211 or other camptothecin, for approximately 10 - 30 minutes against a gradient, such as a membrane potential, generated as the external pH is titrated to the range of 5.0 to 6.5 with sodium hydroxide.
  • the temperature ranges during the drug loading step is generally between 50 - 70°C with lipid:drug ratios between 5:1 to 100:1.
  • camptothecin is generally loaded into pre-formed liposomes using known loading procedures (see for example Deamer et al. BBA 274:323- 335 (1972); Forssen U.S. Patent No. 4,946,683; Cramer et al. BBRC 75:295-301 (1977);
  • the loading can be by gradient or concentration loading, such as pH gradients or ammonium gradients. If a pH gradient is used, it is preferable to begin with an internal pH of approximately pH 2-3.
  • the excipient is the counterion in the loading process and when it comes in contact with the camptothecin in the interior of the liposome, the excipient may cause a substantial portion of the camptothecin to precipitate.
  • the drug may also self precipitate in the interior of the liposome. This precipitation may protect the lactone ring of the camptothecin from
  • An excipient such as citrate or sulfate, may precipitate the camptothecin and can be utilized in the interior of the liposomes together with a gradient (pH or ammonia) to promote camptothecin loading.
  • Drug loading by pH gradient usually includes a low pH in the internal aqueous space of the liposomes, and this internal acidity is incompletely neutralized during the drug loading process.
  • This residual internal acidity can cause chemical instability in the liposomal preparation (e.g., lipid hydrolysis), leading to limitations in shelf life.
  • membrane permeable amines such as ammonium salts or alkyl- amines can be added following the loading of the camptothecin in an amount sufficient to
  • Ammonium salts that can be used include ones having mono-or multi-valent counterions, such as, but not limited to, ammonium sulfate, ammonium hydroxide, ammonium acetate, ammonium chloride, ammonium phosphate, ammonium citrate, ammonium succinate, ammonium lactobionate, ammonium carbonate, ammonium tartrate, and ammonium oxalate.
  • the analogous salt of any alkyl-amine compound which is membrane permeable can also be used, including, but not limited to, methylamine, ethylamine, diethylamine, ethylenediamine, and propylamine.
  • the therapeutic use of liposomes can include the delivery of drugs which are
  • liposomes can also be used therapeutically to release drugs slowly, over a prolonged period of time, thereby reducing the frequency of drug administration through an enhanced pharmacokinetic profile.
  • liposomes can provide a method for forming an aqueous dispersion of hydrophobic drugs for intravenous
  • the route of delivery of liposomes can also affect their distribution in the body. Passive delivery of liposomes involves the use of various routes of administration e.g., parenterally, although other effective administration forms, such as intraarticular injection, inhalant mists, orally active formulations, transdermal iotophoresis or suppositories are also envisioned. Each route produces differences in localization of the liposomes.
  • the invention also provides a method of inhibiting the growth of tumors, both drug resistant and drug sensitive, by delivering a therapeutic or effective amount of liposomal camptothecin to a tumor, preferably in a mammal. Because dosage regimens for camptothecin are well known to medical practitioners, the amount of the liposomal camptothecin
  • camptothecin formulations which is effective or therapeutic for the treatment of the above mentioned diseases or conditions in mammals and particularly in humans will be apparent to those skilled in the art.
  • the optimal quantity and spacing of individual dosages of the formulations herein will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and such optimums can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the optimal course of treatment, i.e., the number of
  • cancers for which the described liposomal formulations may be particularly useful in inhibiting are ovarian cancer, small cell lung cancer (SCLC), non small cell lung cancer (NSCLC), colorectal cancer, breast cancer, and head and neck cancer.
  • SCLC small cell lung cancer
  • NSCLC non small cell lung cancer
  • colorectal cancer breast cancer
  • head and neck cancer ovarian cancer
  • formulations described and claimed herein can be used in combination with existing anticancer
  • the formulations described herein can be used in combination with taxanes such as 1) Taxol (paclitaxel) and platinum complexes for treating ovarian cancer; 2) 5FU and leucovorin or levamisole for treating colorectal cancer; and 3) cisplatin and etoposide for treating SCLC.
  • taxanes such as 1) Taxol (paclitaxel) and platinum complexes for treating ovarian cancer; 2) 5FU and leucovorin or levamisole for treating colorectal cancer; and 3) cisplatin and etoposide for treating SCLC.
  • Example 1 describes the pharmacokinetics of liposomal formulations of Gil 47211 prepared by three different liposome loading techniques.
  • Example 2 describes liposomal formulations of Gil 47211 prepared by gradient loading and the use of ammonia to quench the liposome internal acidity.
  • Example 3 describes precipitation of Gil 47211 salts.
  • Example 4 describes the concentration dependence of precipitation of Gil 47211 salts using selected excipients.
  • Example 5 describes the in vitro efficacy screening and in vivo pharmacokinetics of liposomal formulations of Gil 47211.
  • Example 6 describes the in vivo antitumor efficacy of liposome encapsulated Gil 47211 in comparison to free drug.
  • Example 7 describes the therapeutic index determination of Gil 47211, topotecan and liposomal formulations of
  • Gil 47211 in two separate xenograft models Example 8 describes repeat dose efficacy studies of liposomal formulations of GI 147211 compared to free GI 147211 at equally toxic doses.
  • Example 9 compares two different liposomal preparations of Gil 47211 and free
  • Liposomal Gil 47211 samples were prepared by three different loading techniques: entrapment of the drug in the liposome bilayer, passive entrapment and by active loading against a membrane potential generated by a pH gradient. The pharmacokinetics were then compared for free drug and membrane entrapped Gil 47211 liposomes dosed at 5 mg/kg in Sprague Dawley rats. Rats were dosed at 1 mg/kg to compare free Gil 47211 to passive and actively loaded liposomes.
  • Membrane loaded Gil 47211 liposomes were prepared by first cosolubilizing phospholipid (DSPC), cholesterol and Gil 47211 at a lipid:drug ratio of about 10:1 (w/w) in organic solvent. The solution was dried down to a thin film using nitrogen gas and elevated temperature then stored in a vacuum desiccator under reduced pressure until use.
  • Lipid films were rehydrated with an aqueous solution, typically 9% sucrose and 1 OmM sodium succinate, pH 5.4 in sufficient volume that the lipid concentration was about 50 mg/ml and the Gil 47211 concentration was about 5 mg/ml. Samples were then sonicated for 10-15 minutes above the aggregate lipid phase transition temperature until solutions were translucent in appearance, then filtered through a 0.22 micron filter.
  • an aqueous solution typically 9% sucrose and 1 OmM sodium succinate, pH 5.4 in sufficient volume that the lipid concentration was about 50 mg/ml and the Gil 47211 concentration was about 5 mg/ml.
  • GI147211 liposomes comprised of negative (DSPG) and/or neutrally charged lipids (DSPC) and cholesterol were prepared as follows.
  • Aqueous solutions of GI 147211 C were prepared at drug concentrations of about 30 mg/ml drug by dissolving the drug in a 9% sucrose and 50mM citric acid solution, pH 2.2 at 65°C.
  • Lipid films or spray dried powders were prepared by cosolubilizing the lipid components in an organic solvent system, then drying the solution down to a film or powder using nitrogen gas and elevated temperature. Lipid films or powders were then hydrated at 150 mg/mL lipid to a lipid to drug ratio of 5 : 1 by adding the drug solutions described above, mixing and heating at about 65°C.
  • Particle size diameters were measured to be less than 100 nm using the MicroTrac Ultrafine Particle Analyzer for all small unilamellar vesicles described above with the exception of the membrane loaded sample which had a bimodal size distribution with
  • Gil 47211 samples that were actively loaded against citric acid or ammonium sulfate and in one case quenched with ammonium chloride after loading compared to passive loading. 800-1200 fold increases in AUC, 200 fold increases in C max , 600-1200 fold decreases in clearance rates, and half life extensions ranging from an additional 2 to 7 hours were observed for actively loaded Gil 47211 liposomes compared to free drug.
  • This study demonstrates that the preferred loading method to achieve the best retention of drug with liposomes in vivo is active loading in the presence of a counterion which may precipitate some drug in the internal aqueous core of the liposomes.
  • Example 2 Liposomal Formulations of GI147211
  • Phospholipids and cholesterol used herein were obtained as dry powders from Avanti Polar Lipids, Nippon, Lipoid or Sygena and were used without further purification. All other chemicals were reagent grade and were used without further purification.
  • lipid films or spray dried powders containing various phospholipids including phosphatidylcholine, cholesterol and phosphatidylglycerol were prepared by cosolubilizing the lipid components in an organic solvent system, then drying the solution down to a film or powder using nitrogen gas and elevated temperature.
  • phospholipid sources synthetic, semi-synthetic, egg, soy
  • chain length 14 - 18 carbons
  • degree of unsaturation (1 to 4 double bonds) were explored in the range of molar ratios as shown in Table 3.
  • Each lipid powder or film was hydrated at lipid concentrations of 100 - 150 mg/ml with an aqueous solution containing a counterion solution for
  • Excipient that was not entrapped in the aqueous core of the liposomes was removed from the liposome dispersion generally by buffer exchange to 9% sucrose using dialysis, size exclusion column chromatography (Sephadex G-50 resin) or ultrafiltration (100 kD - 300 kD molecular weight cut off). Each preparation of small unilamellar liposomes was then actively loaded with Gil 47211 for
  • micron filter composed of either cellulose acetate or polyether sulfone. Results of characterization are shown below in Tables 3, 4, 5 and 7.
  • Liposomal Gil 47211 samples so treated exhibited markedly reduced rates of lipid hydrolysis, and thus are rendered more chemically stable relative to untreated samples. Generation of suitably stable liposomal samples with consistent control over lipid hydrolysis rates is required to enhance sample shelf life as a liquid. This is generally a
  • Figure 8 shows accelerated condition (25°C) lipid hydrolysis results for a liposomal Gil 47211 sample prepared with 100 mM citric acid at hydration, followed by loading at a target 20:1 lipid to drug ratio. Following drug loading, the solution was split in half with a control solution and a second sample where ammonium chloride was added. The lipid hydrolysis rate for the sample with ammonium chloride added is dramatically reduced by about 167-fold in comparison to the control system.
  • excipients have been identified which may induce precipitation of Gil 47211 from aqueous media.
  • the excipients include, but are not limited to. the acid, sodium or ammonium forms of monovalent anions such as chloride, acetate, lactobionate and formate; divalent anions such as succinate, aspartate and sulfate; and trivalent ions such as citrate and phosphate.
  • monovalent anions such as chloride, acetate, lactobionate and formate
  • divalent anions such as succinate, aspartate and sulfate
  • trivalent ions such as citrate and phosphate.
  • Example 3 mg/ml solutions of the drug were prepared as described in Example 3 and titrated with increasing concentrations of the counterion excipients sulfate, citrate, phosphate and chloride.
  • the solutions of Gil 47211 and counterion were allowed to stand for 15 to 20 minutes, then centrifuged at 3600 rpm for 10 minutes to isolate the precipitate and the supernatants were assayed as described in Example 3.
  • Figure 1 details the concentration dependence of the precipitation that was observed. Sulfate and citrate are the most efficient and preferred excipients for drug precipitation, reducing the fraction of drug remaining in solution at lower concentrations than chloride or phosphate with no time dependence.
  • Liposomal samples have been prepared by active loading utilizing the counterions listed above and shown in Table 7. Percent loading of drug varied with counterion from 13% (NaCl), 61% (phosphate) to 75% and 89%, respectively for ammonium sulfate and citric acid.
  • Liposomal formulations were prepared as described in Example 2 and samples were characterized as shown in Table 7 below and tested for in vitro efficacy screening and in vivo performance of liposomal Gil 47211.
  • Tumor cells were seeded into 96-well tissue culture plates (lxl 0 4 cells/well) ⁇ 4h prior to experimentation.
  • Tumor cells were then labeled with 0.25 ⁇ Ci of [methyl- 3 H] thymidine and incubated for 42h under tissue culture conditions (37°C, 5% C0 2 , 100% relative humidity), except for C6, U251, A673 and B16- F 1 cells which were incubated for 24h. Cells were then lysed, harvested onto glass-fiber filters and unincorporated [methyl- 3 H] thymidine removed by filter washing. Filters were processed for scintillation counting and cpm- 3 H/well determined. Data (on a cell-type by
  • IC 50 values (50% Inhibitory Concentration) determined for each treatment. Statistical differences were determined by Rank Analysis of Variance with multiple comparisons (no adjustment for multiplicity of testing) to test each cell line for differences in the IC 50 estimates between cells treated with liposomal GI 147211, Gil 47211, and topotecan. IC 50 data are presented for each treatment group (median, minimum, and maximum) with significance indicated (p ⁇ 0.05). Data are presented from multiple sets of experimentation, involving multiple liposomal formulations ofGI147211.
  • DSPCxholesterol are preferred formulations based on increased efficacy data and pharmacokinetic properties.
  • Figure 5 shows the plasma concentrations as a function of
  • liposomal Gil 47211 as a function of time and the plasma pharmacokinetics are summarized in Table 16. Comparison of exposure determined by AUC between free drug and liposomal showed increases of 190 to 500 fold for the three routes of delivery. This study further supports the advantage of liposomal Gil 47211 formulations to increase plasma circulation time and that additional routes of delivery may be utilized to maintain high concentrations in the plasma.
  • the liposomal Gil 47211 appeared to be more efficacious than free drag alone. This is illustrated by both the magnitude of response as well as the duration. This was particularly significant in the multiple drug resistant (MDR+) tumor line KBV, where the free drag had little effect on tumor growth, but the liposomal Gil 47211 demonstrated a dose dependent inhibition of tumor growth. In the two colon tumor xenograft studies, the differences were less pronounced initially, and only apparent in the SW48 tumor study after the second round of treatment. In the HT29 study the difference in tumor response was more dramatic in that the lower 6mg/kg doses of liposomal Gil 47211 were as
  • liposomal Gil 47211 When compared at identical dose and schedule in the SW48 and HT29 colon tumor models, liposomal Gil 47211 produced 95%) tumor growth inhibition in both models compared to 86% and 54%> produced by free drag. A more striking difference was seen in the KB tumor model where liposomal GI147211 demonstrated a Log 10 Cell Kill index of 7.13, compared to 1.64 for free drag. In addition, liposomal Gil 47211 produced 65% tumor growth inhibition in the MDR+ tumor model KBV, whereas the free drug was essentially inactive. When dosed at equally toxic levels, liposomal Gil 47211 was still more efficacious than free drag alone.
  • the established tumor xenograft models used in these studies included the KB head and neck tumor and the ES2 ovarian tumor. All test groups consisted of 10 nude mice, and the drags were delivered as a single intravenous dose bolus injection via the tail vein. Topotecan was dosed from 6 to 40mg/kg, Gil 47211 was dosed from 6-30mg/kg, and liposomal GI147211 was dosed from 3 to 40 mg/kg. The therapeutic index was determined on day 27 post dose, by dividing the LD50 by either the ED60 or ED80. Results from both studies demonstrated that liposomal Gil 47211 has a consistent increase in the therapeutic index ranging from 3 to 14 fold over that of free Gil 47211,
  • NA-908-73 P-9710 Ammonium sulfate DSPC rat 3 0.2 16.20 3.09 4.28 0.012 0.056 NA-908-73 P-9710 Ammonium sulfate DSPC rat 3 1.0 80.54 14.66 8.44 0.013 0.065 NA-908-73 P-9710 Ammonium sulfate DSPC rat 3 5 472.68 75.94 8.63 0.01 1 0.067
  • T-C time difference between treated and control groups to reach 1 ,000% Tumor Volume
  • % Tumor Growth Inhibition(%TGI) 100(l-Wt/Wc); Wt and Wc mean tumor volume of treated and control group
  • T-C Difference in days between treated and control groups to reach 400% tumor volume increase.
  • % TGI 100 ( 1-Wt/Wc ); where Wt is the mean tumor volume of the treated group at day 15 and Wc is the mean tumor volume of the control group at day 15. *See Table 7 for formulation and characterization information. Table 15. Comparison of HSPC (ALM 993-028) vs. DSPC (SC 974-021-1) Liposomal Gil 47211 Formulations and Gil 47211 in the KB Xenograft Model.
  • T-C Time difference between treated and control groups to achieve 400% tumor volume increase.
  • % Tumor Growth Inhibition 100(l-Wt/Wc); Wt and Wc represent mean tumor volume of treated and control groups at day 18.
  • Cure refers to tumor-free animals at day 60.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention se rapporte à des compositions encapsulées à base de liposomes qui renfermant de la camptothécine. Les liposomes présentent des propriétés pharmacocinétiques et une efficacité améliorée en tant qu'agents anti-tumoraux et fournissent un indice thérapeutique accru par rapport à celui d'un médicament libre et du topotécan. Ces compositions renferment des liposomes contenant au moins un phospholipide et une campothécine ou un analogue de cette dernière.
EP98946983A 1997-09-16 1998-09-15 Compositions a base de liposomes renfermant de la camptothecine Withdrawn EP1037610A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5908397P 1997-09-16 1997-09-16
US59083P 1997-09-16
PCT/US1998/019086 WO1999013816A2 (fr) 1997-09-16 1998-09-15 Compositions a base de liposomes renfermant de la camptothecine

Publications (2)

Publication Number Publication Date
EP1037610A1 true EP1037610A1 (fr) 2000-09-27
EP1037610A4 EP1037610A4 (fr) 2004-07-07

Family

ID=22020747

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98946983A Withdrawn EP1037610A4 (fr) 1997-09-16 1998-09-15 Compositions a base de liposomes renfermant de la camptothecine

Country Status (8)

Country Link
EP (1) EP1037610A4 (fr)
JP (1) JP2003510239A (fr)
KR (1) KR100711315B1 (fr)
AU (1) AU751439B2 (fr)
BR (1) BR9812316A (fr)
CA (1) CA2303366A1 (fr)
NZ (1) NZ503293A (fr)
WO (1) WO1999013816A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9914601A (pt) 1998-09-16 2001-10-23 Alza Corp Inibidor de topoisomerase capturado por lipossoma
US7311924B2 (en) 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
US7244448B2 (en) * 2000-06-30 2007-07-17 Tekmira Pharmaceuticals Corporation Liposomal antineoplastic drugs and uses thereof
US6613352B2 (en) 1999-04-13 2003-09-02 Universite De Montreal Low-rigidity liposomal formulation
US7452550B2 (en) 2000-06-30 2008-11-18 Hana Biosciences, Inc. Liposomal antineoplastic drugs and uses thereof
PL363618A1 (en) * 2000-11-09 2004-11-29 Neopharm, Inc. Sn-38 lipid complexes and methods of use
DE10157994A1 (de) * 2001-05-25 2003-01-02 G O T Therapeutics Gmbh Liposomal verkapselte hydrophobe Wirkstoffe mit hohem Wirkstoffgehalt >50% sowie Verfahren zur Herstellung pharmazeutischer Zubereitungen, die liposomal verkapselte hydrophobe Wirkstoffe umfassen
EP1393719A1 (fr) * 2002-08-23 2004-03-03 Munich Biotech AG Compositions à base de carboxylate de camptothécine
EP1553924B1 (fr) * 2002-06-26 2010-12-08 MediGene AG Procede pour stabiliser des composes destines au diagnostic ou a la therapie dans un systeme support cationique
US20040170677A1 (en) * 2002-11-26 2004-09-02 Ning Hu Method of drug loading in liposomes by gradient
US20090285878A1 (en) * 2004-11-05 2009-11-19 Tekmira Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal drug formulations
WO2008070009A2 (fr) * 2006-12-01 2008-06-12 Alza Corporation Procéde de traitement de tumeurs solides et d'une leucémie monocytaire
CN101209243B (zh) 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
TWI428135B (zh) * 2007-03-26 2014-03-01 Hirofumi Takeuchi And a carrier composition for quick-acting nucleic acid delivery
KR101130754B1 (ko) 2010-06-25 2012-03-28 제일약품주식회사 난용성 트리사이클릭 유도체 화합물의 용해도가 향상된 약학적 조성물
AU2013203682B2 (en) * 2011-08-25 2016-03-31 Trophos Liposome comprising at least one cholesterol derivative
FR2979239A1 (fr) * 2011-08-25 2013-03-01 Trophos Liposome comprenant au moins un derive de cholesterol
WO2014047116A1 (fr) * 2012-09-18 2014-03-27 Comfort Care For Animals Llc Liposomes d'encapsulation
CN104837483B (zh) 2012-11-20 2017-09-01 光谱医药公司 制备治疗用途的脂质体封装式长春新碱的改进方法
TWI678213B (zh) 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
KR102162351B1 (ko) 2018-11-08 2020-10-06 순천향대학교 산학협력단 약물-결합 화합물 및 이의 용도
CN115721610A (zh) * 2021-08-27 2023-03-03 沈阳药科大学 一种7-乙基-10-羟基喜树碱复方脂质体及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995008986A1 (fr) * 1993-09-27 1995-04-06 Smithkline Beecham Corporation Compositions de camptothecine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559235A (en) * 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5552156A (en) * 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
US5554382A (en) * 1993-05-28 1996-09-10 Aphios Corporation Methods and apparatus for making liposomes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995008986A1 (fr) * 1993-09-27 1995-04-06 Smithkline Beecham Corporation Compositions de camptothecine

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BURKE T G ET AL: "STABILIZATION OF TOPOTECAN IN LOW PH LIPOSOMES COMPOSED OF DISTEAROYLPHOSPHATIDYLCHOLINE" JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION. WASHINGTON, US, vol. 83, no. 7, 1 July 1994 (1994-07-01), pages 967-969, XP000454801 ISSN: 0022-3549 *
CULLIS PR, MAYER LD, BALLY MB, MADDEN TD, HOPE MJ: "Generating and loading of liposomal systems for drug-delivery applications" ADVANCED DRUG DELIVERY REVIEWS, vol. 3, 1989, pages 267-282, XP002279310 *
DAOUD S S ET AL: "ANTITUMOR EFFECT OF LIPOSOME-INCORPORATED CAMPTOTHECIN IN HUMAN MALIGNANT XENOGRAFTS" ANTI-CANCER DRUGS, RAPID COMMUNICATIONS, OXFORD, GB, vol. 6, no. 1, 1995, pages 83-93, XP000878680 ISSN: 0959-4973 *
See also references of WO9913816A2 *
SUGARMAN S ET AL: "LIPOSOMAL CAMPTOTHECIN: FORMULATION AND CYTOTOXICITY AGAINST KB CELLS" PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. ORLANDO, MAY 19 - 22, 1993, PHILADELPHIA, AACR, US, vol. MEETING 84, 1 March 1993 (1993-03-01), page 422 XP000578376 ISSN: 0197-016X *

Also Published As

Publication number Publication date
KR100711315B1 (ko) 2007-04-27
BR9812316A (pt) 2001-03-20
AU751439B2 (en) 2002-08-15
WO1999013816A3 (fr) 2001-11-01
AU9387798A (en) 1999-04-05
JP2003510239A (ja) 2003-03-18
WO1999013816A2 (fr) 1999-03-25
NZ503293A (en) 2002-09-27
KR20010030599A (ko) 2001-04-16
EP1037610A4 (fr) 2004-07-07
CA2303366A1 (fr) 1999-03-25

Similar Documents

Publication Publication Date Title
AU751439B2 (en) Liposomal camptothecin formulations
AU774715B2 (en) Liposome-entrapped topoisomerase inhibitors
US6740335B1 (en) Liposomal camptothecin formulations
Tardi et al. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo
JP4990786B2 (ja) 薬物リポソーム製剤を安定化するための組成物および方法
US20050238706A1 (en) Pharmaceutically active lipid based formulation of SN-38
JP2021183654A (ja) 安定化カンプトテシン医薬組成物
US8709474B2 (en) Liposomes with improved drug retention for treatment of cancer
EP1553923B1 (fr) Formulations de camptoth cine-carboxylate
WO2005002546A1 (fr) Compositions liposomales stabilisee de topotecane et procedes
KR100387744B1 (ko) 수불용성캄프토테신의지질복합체의동결건조물을포함하는약제학적조성물
AU2001275269B2 (en) Liposomal benzoquinazoline thymidylate synthase inhibitor formulations
Hao et al. In vitro and in vivo studies of different liposomes containing topotecan
US20070231379A1 (en) Liposome-entrapped topoisomerase inhibitors
US10980798B2 (en) Pharmaceutical compositions of hydrophobic camptothecin derivatives
MXPA01003796A (en) Liposome-entrapped topoisomerase inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000417

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20000417;LT PAYMENT 20000417;LV PAYMENT 20000417;MK PAYMENT 20000417;RO PAYMENT 20000417;SI PAYMENT 20000417

D17D Deferred search report published (deleted)
D17D Deferred search report published (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: OSI PHARMACEUTICALS, INC.

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 31/4745 B

Ipc: 7A 61K 9/127 A

A4 Supplementary search report drawn up and despatched

Effective date: 20040526

17Q First examination report despatched

Effective date: 20040827

17Q First examination report despatched

Effective date: 20040827

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091006

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1031103

Country of ref document: HK